e-Drug3D

1482

PAZOPANIB

INN
PAZOPANIB

cas 444731-52-6

CLASS

ANTINEOPLASTIC
PROTEIN KINASE INHIBITORS
RENAL CELL CARCINOMA
SOFT TISSUE SARCOMA

ROUTE (list)

ORAL

ATC code

L01EX03

PK parameters

Tmax 3 HOUR
PPB 99 PERCENT
t1/2 30.9 HOUR (800 MILLIGRAM)

Solubility

PRACTICALLY INSOLUBLE ABOVE PH 4 IN WATER

Target

TARGET VEGFR-1
VEGFR-2
VEGFR-3
PDGFR-ALPHA
PDGRF-BETA
FGFR-1
FGFR-3
KIT
ITK
LCK
TRANSMEMBRANE GLYCOPROTEIN RECEPTOR TYROSINE KINASE (C-FMS)

DrugCentral

Platelet-derived growth factor receptor beta UNIPROT P09619 PDGFRB

Mast,stem cell growth factor receptor Kit UNIPROT P10721 KIT

Download SDF file

Benzenesulfonamide, 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-

Formula:
C21H23N7O2S

Calculated chemical properties:

MW 437.53
NB_atoms 31
XLogP 3.14
PSA 105.541
NB_HD 3
NB_HA 9
fsp3 0.19
Lipinski(0=no;1=yes) 1

FDA
NDA 022465 (pdf not found) INN (PAZOPANIB HYDROCHLORIDE) VOTRIENT (NOVARTIS) APPROVAL= AP YEAR= 2009
NDA 215837 (pdf not found) INN (PAZOPANIB HYDROCHLORIDE) PAZOPANIB HYDROCHLORIDE (SUN PHARM) APPROVAL= AP YEAR= 2023
NDA 217517 (pdf not found) INN (PAZOPANIB HYDROCHLORIDE) PAZOPANIB HYDROCHLORIDE (TEVA PHARMS INC) APPROVAL= AP YEAR= 2023
NDA 217713 (pdf not found) INN (PAZOPANIB HYDROCHLORIDE) PAZOPANIB HYDROCHLORIDE (APOTEX) APPROVAL= AP YEAR= 2023
NDA 218231 (pdf not found) INN (PAZOPANIB HYDROCHLORIDE) PAZOPANIB HYDROCHLORIDE (NOVUGEN) APPROVAL= AP YEAR= 2024
NDA 219034 (pdf not found) INN (PAZOPANIB HYDROCHLORIDE) PAZOPANIB HYDROCHLORIDE (EUGIA PHARMA) APPROVAL= AP YEAR= 2024